CryoCath Announces Settlement of Pending Suits with CryoCor, Inc. (Boston Scientific) and AMS Research Corp.



    
    www.cryocath.com
    Toronto Stock Exchange Symbol: CYT
    

    MONTREAL, Sept. 25 /CNW/ - CryoCath(R) Technologies Inc. (TSX: CYT.TO)
announced today that it has resolved all outstanding patent suits among the
company and Boston Scientific Corporation (NYSE:   BSX), its wholly-owned
subsidiary, CryoCor, Inc., and CryoCor's co-plaintiff/co-defendant AMS
Research Corporation. The companies have a number of court actions pending
involving cryoablation systems in the United States and Canada and an
International Trade Commission investigation each of which they have agreed to
terminate.
    As part of the settlement, the companies have agreed to mutual covenants
that provide for all of the existing litigation to be withdrawn and an
agreement by all parties not to sue each other in regards to certain other
cryoablation-related intellectual property over the next twelve years. As part
of the terms of the resolution, CryoCath has agreed to the payment of
royalties on certain future products for a limited time. The companies have
also agreed to permit the two Interference proceedings pending with the United
States Patent and Trademark Office Board of Patent Appeals and Interferences
to proceed, but regardless of the outcome, the surviving patent(s) will be
subject to the covenants not to sue.
    "We believe this is a positive and far-reaching resolution of the
disputes among CryoCath, Boston Scientific and the related parties," said Jan
Keltjens, President and CEO of CryoCath. "The resolution of these disputes
reflects the value of CryoCath's intellectual property and allows us to focus
our resources on driving our rapid business growth."

    About CryoCath

    CryoCath - www.cryocath.com - is a medical technology company that leads
the world in cryotherapy products to treat cardiac arrhythmias. With annual
sales in excess of $40 million, its products are routinely used in more than
500 centers around the world. The Company's flagship product, Arctic Front(R),
is a minimally invasive cryo-balloon catheter designed specifically to treat
Atrial Fibrillation, an emerging $2 billion market opportunity. Marketed in
Europe and the subject of a pivotal study in the United States, Arctic Front
has been used to treat 3,100 patients.

    This press release includes "forward-looking statements" that are subject
to risks and uncertainties, including with respect to the timing of regulatory
trials and their outcome. For information identifying legislative or
regulatory, economic, climatic, currency, technological, competitive and other
important factors that could cause actual results to differ materially from
those anticipated in the forward looking statements, see CryoCath's annual
report available at www.sedar.com under the heading Risks and Uncertainties in
the Management's Discussion and Analysis section.

    %SEDAR: 00015053EF




For further information:

For further information: visit our website at www.cryocath.com, or
contact: Ross Marshall, Investor Relations, Phone: (416) 815-0700 ext.238,
Fax: (416) 815-0080, E-mail: rmarshall@equicomgroup.com

Organization Profile

CRYOCATH TECHNOLOGIES INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890